Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics, Inc. furnished a press release announcing its financial results for the third fiscal quarter ended June 30, 2025. The company released these results through a press release dated August 14, 2025, which is attached as Exhibit 99.1. The disclosure is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Outlook Therapeutics, Inc. Schedule 13G/A reports that Tang Capital entities and Kevin Tang collectively beneficially own 1,500,000 shares of the company's common stock, representing 3.4% of the outstanding class on a diluted basis. Those shares are currently issuable upon exercise of warrants held by Tang Capital Partners, LP, and the filing states the percentages are based on 43,692,728 shares (42,192,728 outstanding plus 1,500,000 issuable warrants). TCP's warrants are exercisable for one share each but include a beneficial ownership cap preventing exercise that would increase ownership above 9.99% unless TCP provides notice to increase to a maximum of 19.99% with a 61-day delay. Voting and dispositive power over the shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang.